SCHEMBL3206847

SCHEMBL3206847

CC(C)c1cc(C=O)n(Cc2ccc(C(F)(F)F)cc2Cl)n1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARG P37231 8/20 0.49
PTGDR2 Q9Y5Y4 2/20 0.41
KCNJ6 P48051 1/20 0.40
KCNJ5 P48544 1/20 0.40
KCNJ3 P48549 1/20 0.40
PDE2A O00408 1/20 0.38
CCR2 P41597 1/20 0.38
DAO P14920 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
P2RX7 Q99572 1/20 0.36
TRPV1 Q8NER1 1/20 0.36
FAAH O00519 1/20 0.36
NR1I2 O75469 1/20 0.35
NR3C1 P04150 1/20 0.35
AR P10275 1/20 0.35
RXRA P19793 1/20 0.35
NR1H2 P55055 1/20 0.35
NR1H3 Q13133 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3204742 0.85 PPARG (0.54) PPARGPTGDR2KCNJ6KCNJ5KCNJ3
SCHEMBL3204752 0.85 PPARG (0.54) PPARGPTGDR2KCNJ6KCNJ5KCNJ3
SCHEMBL3204805 0.85 NPC1 (0.48) PPARGPTGDR2CCR2DAONPSR1
SCHEMBL3216020 0.84 PPARG (0.54) PPARGNPSR1
SCHEMBL3215911 0.81 PPARG (0.53) PPARGPTGDR2CCR2DAONPSR1
SCHEMBL3210877 0.81 PPARG (0.59) PPARGPTGDR2KCNJ6KCNJ5KCNJ3
SCHEMBL4613928 0.80 NPC1 (0.54) PPARGPTGDR2KCNJ6KCNJ5KCNJ3
SCHEMBL3205336 0.80 PPARG (0.57) PPARGPTGDR2KCNJ6KCNJ5KCNJ3
SCHEMBL3207559 0.79 PPARG (0.53) PPARGPTGDR2CCR2
SCHEMBL4614768 0.77 PPARG (0.45) PPARGPTGDR2KCNJ6KCNJ5KCNJ3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041892-A1 Therapeutic agent for diabetes ABE HIDENORI 2010-02-18 US disclosed
US-20090270631-A1 Therapeutic agent for diabetes ABE HIDENORI 2009-10-29 US disclosed
CN-101282725-A Therapeutic agent for diabetes TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2008-10-08 CN disclosed
EP-1912645-A2 THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2008-04-23 EP disclosed
US-20080051418-A1 Arylalkanoic Acid Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-02-28 US disclosed
US-20080009530-A1 Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-10 US disclosed
EP-1829863-A1 ARYLALKANOIC ACID DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2007-09-05 EP disclosed
WO-2007018314-A2 THERAPEUTIC AGENT FOR DIABETES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270631-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 PPARG 31/4885PTGDR2 1289/4885KCNJ6 3589/4885
US-20080051418-A1 Arylalkanoic Acid Derivative INSR, NPY1R, GPR119 PPARG 52/4885PTGDR2 2631/4885KCNJ6 859/4885
US-20080009530-A1 Therapeutic Agent for Diabetes FABP4, SLC5A1, SLC5A2 PPARG 30/4885PTGDR2 1005/4885KCNJ6 3134/4885
US-20100041892-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 PPARG 31/4885PTGDR2 1289/4885KCNJ6 3589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.